Circulating neuron-specific enolase in medullary thyroid cancer.

Area of Science:

• Oncology
• Biochemistry
• Endocrinology

Background:

• Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor.
• Accurate tumor markers are crucial for MTC management.
• Neuron-specific enolase (NSE) is a potential biomarker.

Purpose of the Study:

• To evaluate the utility of serum neuron-specific enolase (NSE) as a biomarker in medullary thyroid carcinoma (MTC).
• To correlate NSE levels with disease status, calcitonin (CT) levels, and prognosis in MTC patients.

Main Methods:

• Prospective study of 25 MTC patients over a mean follow-up of 45.6 months.
• Serum NSE and calcitonin (CT) levels were measured.
• Correlation of NSE levels with treatment, remission, disease evidence, and metastases.

Main Results:

• Pre-treatment NSE levels were normal.
• Abnormally high NSE (>9.8 ng/ml) was found in patients with elevated CT and metastases (9/12).
• Mean NSE was significantly higher in patients with metastases (12.0 ng/ml) compared to other groups (p<0.005).
• NSE levels paralleled CT levels and tumor burden, decreasing after effective treatment.

Conclusions:

• Serum NSE is a valuable additional humoral marker for medullary thyroid carcinoma.
• Elevated NSE is associated with metastatic involvement and a poorer prognosis.
• NSE monitoring can aid in assessing tumor burden and response to therapy.